Investors & Media
Contact

Home
About Us
Our Approach
Pipeline
Patients & Caregivers
- Acute Leukemias
- Head & Neck Cancer
Clinical Trials
Careers
Investors & Media
Contact
Menu Menu

Navigating dose optimization requirements as a small biotech

February 1, 2023/in Currents

https://kuraoncology.com/wp-content/uploads/BioCentury_0201_DB_DoseOptim.png 646 1246 Ellie Solorio /wp-content/uploads/kura-logo.svg Ellie Solorio2023-02-01 08:00:002023-02-07 14:03:52Navigating dose optimization requirements as a small biotech

About Us
Our Commitment
The Story Behind Our Name
Leadership
Board of Directors

Our Approach
Precision Medicines
Overcoming Resistance
Novel Biomarkers

Pipeline
Ziftomenib
Tipifarnib
KO-2806
Posters and Publications
Access to Investigational Drugs Outside a Clinical Study

Patients & Caregivers
Acute Leukemias
Head & Neck Cancer

Clinical Trials
Overview of Clinical Trials
Ziftomenib Clinical Trials
KOMET-001 – AML
Tipifarnib Clinical Trials
AIM-HN – HNSCC
KURRENT-HN – HNSCC
KURRENT-LUNG

Investors & Media
Overview
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Analyst Coverage
FAQs
Contact

Careers
Values
Life at Kura
Benefits
Open Positions

Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

On the prickly issues facing the Menin inhibitors